|
[1]
|
Vaidyanathan G, Zhao XG, Larsen RH, et al. 3-[211At]-astato-4-fluorobenzylguanidine:a potential therapeutic agent with prolonged retention by neuroblastoma cells[J]. Br J Cancer, 1997, 76(2):226-233. |
|
[2]
|
Cunningham SH, Maris RJ, Wheldon TE, et al. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissio[J]. Br J Cancer, 1998, 77(12):2016-2018. |
|
[3]
|
Zhuang ZP, Kung MP, Mu MU, et al. 99Tcm-labelled MIBG derivatives:Novel 99Tcm complexes as myocardial imaging agents for sympathetic neurons[J]. Bioconjugate Chem, 1999,10(2):159-168. |
|
[4]
|
Stevens MJ, Raffel DM, Allman KC, et al. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes:an assessment by C-11 hydroxyephedrine and positron emission tomography[J]. Metabolism, 1999, 48(1):92-101. |
|
[5]
|
Merlet P, Pouillart F, Dubois-Rande JD, et al. Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart[J]. J Nucl Med, 1999, 40:224-231. |
|
[6]
|
Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy[J]. J Nucl Med, 1999, 40:917-923. |
|
[7]
|
Maunoury C, Agostini D, Acar P, et al. Impairment of cardiac neuronal function in children dilated cardiomyopathy:an 123I-MIBG scintigraphic Study[J]. J Ncul Med, 2000, 41:400-404. |
|
[8]
|
Bengel FM, Barthel P, Matsunari I, et al. Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy[J]. J Nucl Med, 1999, 40:904-910. |
|
[9]
|
Sakata K, Shirotani M, Yoshida H, et al. Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG[J]. J Nucl Med, 1999, 40:6-11. |
|
[10]
|
Estorch M, Camprecios M, Flotats A, et al. Sympathetic reinnervation of cardiac allografts evaluated by 123I-MIBG imaging[J]. J Nucl Med, 1999, 40:911-916. |
|
[11]
|
Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease:clinical and experimental studies with radiolabelled MIBG[J]. J Nucl Med, 2000, 41(1):71-77. |
|
[12]
|
Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG SPECT[J]. J Neurol Sci, 2000, 175(1):3-12. |
|
[13]
|
Reinhardt MJ, Jungling FD, Krause TM, et al. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction:value of cardiac and pulmonary iodine-123 MIBG uptake[J]. Eur J Nucl Med, 2000, 27(5):595-600. |
|
[14]
|
Owens J, Bolster AA, Prosser JE, et al. No-carrier-added 123I-MIBG:an initial clinical study in patients with phaeochromocytoma[J]. Nucl Med Commun, 2000, 21(5):437-440. |
|
[15]
|
Kuin A, Rutgers M, van der Valk MA, et al. Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)[J]. Br J Cancer, 1999, 79(5-6):802-806. |
|
[16]
|
Boyd M, Cunningham SH, Brown MM, et al. Noradrenaline transporter gene transfer for radiation cell kill by 131I metaiodobenzylguanidine[J]. Gene Ther, 1999, 6(6):1147-1152. |
DownLoad: